## Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer’s disease in the EMIF-AD study.

Rebecca G. Smith<sup>1</sup>, Ehsan Pishva<sup>1,2</sup>, Morteza Kouhsar<sup>1</sup>, Jennifer Imm<sup>1</sup>, Valerija Dobricic<sup>3</sup>, Peter Johannsen<sup>4</sup>, Michael Wittig<sup>5</sup>, Andre Franke<sup>5</sup>, Rik Vandenberghe<sup>6</sup>, Jolien Schaeverbeke<sup>6</sup>, Yvonne Freund-Levi<sup>7,8,9</sup>, Lutz Frölich<sup>10</sup>, Philip Scheltens<sup>11</sup>, Charlotte E. Teunissen<sup>12</sup>, Giovanni Frisoni<sup>13</sup>, Olivier Blin<sup>14</sup>, Jill C. Richardson<sup>15</sup>, Régis Bordet<sup>16</sup>, Sebastiaan Engelborghs<sup>17,18</sup>, Ellen de Roeck<sup>17</sup>, Pablo Martinez-Lage<sup>19</sup>, Miren Altuna<sup>19</sup>, Mikel Tainta<sup>19</sup>, Alberto Lleó<sup>20</sup>, Isabel Sala<sup>20</sup>, Julius Popp<sup>21</sup>, Gwendoline Peyratout<sup>22</sup>, Laura Winchester<sup>23</sup>, Alejo Nevado-Holgado<sup>23</sup>, Frans Verhey<sup>2</sup>, Magda Tsolaki<sup>24</sup>, Ulf Andreasson<sup>25</sup>, Kaj Blennow<sup>25,26,27</sup>, Henrik Zetterberg<sup>25,28,29,30,31</sup>, Johannes Streffer<sup>32</sup>, Stephanie J. B. Vos<sup>2</sup>, Simon Lovestone<sup>22,33</sup>, Pieter Jelle Visser<sup>2,11</sup>, Lars Bertram<sup>3</sup> and Katie Lunnon<sup>1,*</sup>

<ol>
<li>Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences, University of Exeter, Exeter, Devon, EX2 5DW, United Kingdom. </li>
<li>Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNs), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Universiteitssingel 40, 6229 ER, Maastricht, The Netherlands.</li>
<li>Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Maria-Goeppert-Straße 1, 23562 Lübeck, Germany.</li>
<li>Danish Dementia Research Centre, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.</li>
<li>Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Rosalind-Franklin-Straße 12, 24105, Kiel, Germany.</li>
<li>Laboratory for Cognitive Neurology, KU Leuven, Leuven Brain Institute, UZ Herestraat 49 - bus 7003 3000, Leuven, Belgium.</li>
<li>Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, 118 83 Stockholm, Sweden.</li>
<li>School of Medical Sciences, Örebro University, SE-701 82 Örebro, Sweden.</li>
<li>Department of Geriatrics, Södertälje Hospital, Rosenborgsgatan 10, 152 40 Södertälje, Sweden.</li>
<li>Department of Geriatric Psychiatry, Central Institut of Mental Health, Medical Faculty Mannheim/Heidelberg University, J5, 68159, Mannheim, Germany.</li>
<li>Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1108, 1081 HV Amsterdam, The Netherlands.</li>
<li>Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1108, 1081 HV Amsterdam, The Netherlands. </li>
<li>Memory center, Geneva University and University Hospitals; on behalf of the AMYPAD consortium. Rue Gabrielle-Perret-Gentil 4, 1205 Genève, Geneva, Switzerland.</li>
<li>Aix-Marseille University-CNRS, 163 Avenue de Luminy Case 901, 13288, Marseille, France.</li>
<li>Neuroscience Therapeutic Area, GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, United Kingdom.</li>
<li>Université de Lille, CHU, 1, Place de Verdun, 59045, Lille Cedex, France.</li>
<li>Department of Biomedical Sciences, University of Antwerp, Universiteitsbaan 212, 2610 Antwerp, Belgium.</li>
<li>Neuroprotection & Neuromodulation (NEUR) Research Group, Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, Jette, Brussels, 1090, Belgium. </li>
<li>Center for Research and Advanced Therapies, Fundación CITA-Alzhéimer Fundazioa, Mikeletegi 71, 20009 Donostia-San Sebastian, San Sebastian, Gipuzkoa, Spain.</li>
<li>Servicio de Neurología, Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Hospital Sant Pau, Sant Antoni Maria Claret, 167 08025 Barcelona, Spain.</li>
<li>University Hospital of Psychiatry Zürich, University of Zürich, Lenggstrasse 31, 8032 Zürich, Switzerland.</li>
<li>Department of Psychiatry, University Hospital of Lausanne (CHUV), Place Chauderon 18, 1003 Lausanne, Switzerland.</li>
<li>Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, United Kingdom</li>
<li>1st Department of Neurology, School of Medicine, Laboratory of Neurodegenerative Diseases, Center for Interdisciplinary Research and Innovation, Aristotle University of Thessaloniki, and Alzheimer Hellas, Macedonia, Balkan Center, Buildings A & B, Thessaloniki, 10th km Thessaloniki-Thermi Rd, P.O. Box 8318, GR 57001, Greece.</li>
<li>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Blå stråket 5, 413 45 Göteborg, Sweden.</li>
<li>Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, 47 Bd de l'Hôpital, 75013 Paris, France.</li>
<li>Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, 96 Jinzhai Road, Hefei, China 230026, Hefei, P.R. China.</li>
<li>Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom. </li>
<li>UK Dementia Research Institute at UCL, 6th Floor, Maple House, Tottenham Ct Rd, London W1T 7NF, United Kingdom.</li>
<li>Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Units 1501-1502, 1512-1518, 15/F, Building 17W, Hong Kong Science Park, Shatin, N.T., Hong Kong, China.</li>
<li>Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, 600 Highland Avenue, MC 2420, Madison, Wisconsin 53792-2420, USA.</li>
<li>Translational Medicine Neuroscience, UCB Biopharma SRL, Chemin du Foriest, B-1420 Braine-l’Alleud, Brussels, Belgium.</li>
<li>Currently at: Johnson & Johnson Innovative Medicines, Turnhoutseweg 30, 2340 Beerse, Belgium.</li>

</ol>
  
<sup>*</sup> Corresponding author: Katie Lunnon, University of Exeter Medical School, RILD, Barrack Road, University of Exeter, Devon, UK. UK. Tel: + 44 1392 408 298 Email address: k.lunnon@exeter.ac.uk

<p><B></B>Abstract</p></p>
<p>INTRODUCTION: 
<br>We investigated blood DNA methylation patterns associated with 15 well-established cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD) pathophysiology, neuroinflammation and neurodegeneration.</p> 
<p>METHODS:
<br>We assessed DNA methylation in 885 blood samples from the European Medical Information Framework for Alzheimer’s Disease (EMIF-AD) study using the EPIC array.</p>  
<p>RESULTS:
<br>We identified Bonferroni-significant differential methylation associated with CSF YKL-40 (five loci) and neurofilament light chain (NfL; seven loci) levels, with two of the loci associated with CSF YKL-40 levels correlating with plasma YKL-40 levels. A co-localization analysis showed shared genetic variants underlying YKL-40 DNA methylation and CSF protein levels, with evidence that DNA methylation mediates the association between genotype and protein levels. Weighted gene correlation network analysis identified two modules of co-methylated loci correlated with several amyloid measures and enriched in pathways associated with lipoproteins and development.</p> 
<p>DISCUSSION:
<br>We conducted the most comprehensive epigenome-wide association study (EWAS) of Alzheimer’s disease-relevant CSF biomarkers to date. Future work should explore the relationship between YKL-40 genotype, DNA methylation and protein levels in the brain.</p> 

